Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.

TU E; SWENSON LC; LAND S; EMERY S; MARKS K; KELLEHER AD; KAYE S; KAISER R; SCHUELTER E; HARRIGAN R; MARCH LABORATORY GROUP ; MARCH STUDY GROUP; SALOMON H. (MARCH STUDY GROUP)

JOURNAL OF CLINICAL MICROBIOLOGY

AMER SOC MICROBIOLOGY

Lugar: Washington; Año: 2013 vol. 51 p. 2063 - 2071

0095-1137

MARCH, a maraviroc switch study in aviraemic patients on stable antiretroviral therapy, utilises population-based sequencing of proviral DNA to determine HIV-tropism and susceptibility to maraviroc. An external quality assurance (EQA) programme was implemented to ensure competency in assessing tropism of clinical samples by MARCH laboratories (n=14). Methods MARCH EQA has three pre-study phases assessing V3-loop sequencing and tropism determination using the bioinformatic algorithm geno2pheno, which generates a false positive rate (FPR). Sequences with low FPRs are more likely to be CXCR4-using (X4). Phase 1 of EQA, involved chromatogram interpretation. Phases 2, 2/3 and 3 involved patient and clonal samples. Clinical samples used in these phases were from treatment-experienced HIV-infected volunteers; 18/20 with viral loads